#1 Clinical Trials Search in Europe

Valiltramiprosate

This article discusses the ongoing clinical trials of Valiltramiprosate, also known as ALZ-801, for the treatment of early Alzheimer’s disease. The drug is being studied in patients aged 50-80 who carry specific genetic variants associated with increased risk of Alzheimer’s. The trials aim to evaluate the drug’s effects on various biomarkers of Alzheimer’s disease, brain volumes, and cognitive function over an extended period.

Table of Contents

What is VALILTRAMIPROSATE?

VALILTRAMIPROSATE, also known as ALZ-801, is a new medication being studied for the treatment of early Alzheimer’s disease (AD)[1]. It is a tablet taken orally and is currently in Phase 2 clinical trials. This means that while it shows promise, it is still being tested to determine its effectiveness and safety.

How does it work?

VALILTRAMIPROSATE is designed to target the underlying causes of Alzheimer’s disease. It aims to reduce the levels of harmful proteins in the brain that are associated with AD, specifically:

  • Amyloid-beta (Aβ): A protein that forms plaques in the brains of Alzheimer’s patients
  • Tau protein: Another protein that can form tangles in brain cells of people with AD
By reducing these proteins, researchers hope that VALILTRAMIPROSATE can slow down or potentially stop the progression of Alzheimer’s disease[1].

Who can benefit from VALILTRAMIPROSATE?

The current research is focusing on people who meet the following criteria:

  • Ages 50-80 years old
  • Diagnosed with early Alzheimer’s disease or Mild Cognitive Impairment (MCI) due to AD
  • Carriers of a specific genetic variant called APOE4 (either APOE4/4 or APOE3/4)
  • Showing signs of AD in their brain, confirmed by tests like amyloid PET scans or cerebrospinal fluid (CSF) analysis
It’s important to note that this medication is specifically targeting individuals in the early stages of Alzheimer’s disease who have a particular genetic profile[1].

Current Research

The ongoing clinical trial is designed to evaluate several aspects of VALILTRAMIPROSATE:

  1. Biomarkers: The study is measuring changes in proteins in the blood and CSF that are associated with Alzheimer’s disease. This includes p-tau181, which is a form of the tau protein[1].
  2. Brain imaging: Researchers are using MRI scans to measure changes in brain volume, particularly in the hippocampus, an area important for memory[1].
  3. Cognitive tests: Participants are undergoing various tests to measure their memory, thinking skills, and ability to perform daily activities[1].
  4. Safety: The study is closely monitoring for any side effects or safety concerns[1].
The trial is planned to last for 104 weeks (2 years), with potential extensions for up to 4 years to assess long-term effects[1].

Potential Benefits

If successful, VALILTRAMIPROSATE could offer several benefits for people with early Alzheimer’s disease:

  • Slowing down the progression of the disease
  • Preserving memory and cognitive function
  • Maintaining ability to perform daily activities
  • Potentially delaying the need for intensive care
However, it’s crucial to remember that these potential benefits are still being studied and have not yet been proven[1].

Safety and Side Effects

As with any medication, safety is a top priority in the VALILTRAMIPROSATE trials. The researchers are carefully monitoring for any side effects or adverse reactions. Some areas they’re paying close attention to include:

  • Changes in liver function
  • Effects on kidney function
  • Changes in heart rhythm
  • Any neurological side effects
It’s important to note that the full safety profile of VALILTRAMIPROSATE is still being determined through these clinical trials[1].

Conclusion

VALILTRAMIPROSATE (ALZ-801) represents a promising new approach in the fight against Alzheimer’s disease. By targeting the underlying causes of AD in its early stages, researchers hope to find a way to slow or stop the progression of this devastating condition. However, it’s important to remember that this medication is still in the testing phase. More research is needed to fully understand its effectiveness and safety. If you or a loved one are interested in learning more about Alzheimer’s treatments, it’s always best to consult with a healthcare professional who can provide personalized advice based on individual circumstances[1].

Aspect Details
Drug Name Valiltramiprosate (ALZ-801)
Trial Phase Phase 2
Target Population Adults aged 50-80 with early Alzheimer’s disease and APOE4/4 or APOE3/4 genotype
Primary Outcomes Changes in plasma p-tau181 and hippocampal volume
Secondary Outcomes Safety, changes in other biomarkers, cognitive function, brain imaging measures
Duration Initial 104 weeks with potential extensions up to 208 weeks
Administration Oral tablet, up to 530 mg daily
Key Assessments Blood tests, CSF analysis, brain MRI, cognitive tests

FAQ

  • What is Valiltramiprosate (ALZ-801)? Valiltramiprosate, also known as ALZ-801, is an investigational drug being studied for the treatment of early Alzheimer's disease. It is taken orally in tablet form.
  • Who is eligible for these clinical trials? The trials are designed for individuals aged 50-80 with early Alzheimer's disease who carry specific genetic variants (APOE4/4 or APOE3/4) associated with increased risk of Alzheimer's.
  • What are the main objectives of these trials? The main objectives are to evaluate the effects of ALZ-801 on plasma biomarkers of Alzheimer's disease pathology, brain volumes (particularly hippocampal volume), and cognitive function in eligible participants.
  • How long do these clinical trials last? The initial study period is 104 weeks (2 years), with potential long-term extensions for up to 208 weeks (4 years) in total.
  • What types of assessments are performed during the trials? Participants undergo various assessments, including blood and cerebrospinal fluid tests, brain MRI scans, cognitive tests, and safety evaluations throughout the study period.

Ongoing Clinical Trials on Valiltramiprosate

  • Study on the Effects of ALZ-801 in Patients Aged 50-80 with Early Alzheimer’s Disease and APOE4 Genotype

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia The Netherlands

Glossary

  • Alzheimer's disease (AD): A progressive brain disorder that affects memory, thinking skills, and the ability to carry out simple tasks.
  • APOE4: A genetic variant associated with increased risk of developing Alzheimer's disease.
  • Biomarker: A measurable indicator of a biological state or condition, often used to track disease progression or treatment effects.
  • Cerebrospinal fluid (CSF): Clear fluid surrounding the brain and spinal cord, often used for diagnostic tests in neurological disorders.
  • Hippocampus: A region of the brain important for memory formation and often affected early in Alzheimer's disease.
  • MCI (Mild Cognitive Impairment): A condition characterized by minor cognitive decline that doesn't significantly affect daily life, but may progress to dementia.
  • MMSE (Mini-Mental State Examination): A widely used test to measure cognitive impairment and screen for dementia.
  • Plasma: The liquid component of blood, often used for biomarker analysis.
  • p-tau: Phosphorylated tau protein, a biomarker associated with Alzheimer's disease pathology.
  • vMRI (Volumetric Magnetic Resonance Imaging): An imaging technique used to measure brain volumes and track changes over time.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-alz-801-in-patients-aged-50-80-with-early-alzheimers-disease-and-apoe4-genotype/